Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Inflammatory Bowel Diseases

Free Subscription Articles published in Gut Retrieve available abstracts of 122 articles: HTML format Text format

Single Articles

January 2012
1. KHALILI H , Huang ES, Ananthakrishnan AN, Higuchi L, et al
   Geographical variation and incidence of inflammatory bowel disease among US women.
   Gut. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. SIEGMUND B
   Mesenteric fat in Crohn's disease: the hot spot of inflammation?
   Gut. 2012;61:3-5.
   PubMed     Text format     Related articles   
   
   
   
   
3. PEYRIN-BIROULET L , Gonzalez F, Dubuquoy L, Rousseaux C, et al
   Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease.
   Gut. 2012;61:78-85.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. ZULIAN A , Cancello R, Micheletto G, Gentilini D, et al
   Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease?
   Gut. 2012;61:86-94.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. OP DE BEECK K , Vermeire S, Rutgeerts P, Bossuyt X, et al
   Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases.
   Gut. 2012;61:162-4.
   PubMed     Text format     Related articles   
   
   
   
   December 2011
6. SIEGEL CA
   Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options.
   Gut. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. JESS T , Frisch M, Jorgensen KT, Pedersen BV, et al
   Increased risk of inflammatory bowel disease in women with endometriosis: a nationwide Danish cohort study.
   Gut. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. BEAUGERIE L
   Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?
   Gut. 2011.
   PubMed     Text format     Related articles   
   
   
   
   
9. ORDAS I , Feagan BG, Sandborn WJ
   Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change.
   Gut. 2011;60:1754-63.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. SHENG YH , Lourie R, Linden SK, Jeffery PL, et al
    The MUC13 cell-surface mucin protects against intestinal inflammation by inhibiting epithelial cell apoptosis.
    Gut. 2011;60:1661-70.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. LEES CW , Barrett JC, Parkes M, Satsangi J, et al
    New IBD genetics: common pathways with other diseases.
    Gut. 2011;60:1739-53.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
12. KIESSLICH R , Duckworth CA, Moussata D, Gloeckner A, et al
    Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. DANESE S
    New therapies for inflammatory bowel disease: from the bench to the bedside.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. WERNER L , Berndt U, Paclik D, Danese S, et al
    TNFalpha inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. HAAS A , Zimmermann K, Graw F, Slack E, et al
    Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection.
    Gut. 2011;60:1506-19.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. UZA N , Nakase H, Yamamoto S, Yoshino T, et al
    SR-PSOX/CXCL16 plays a critical role in the progression of colonic inflammation.
    Gut. 2011;60:1494-505.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. FRITZ T , Niederreiter L, Adolph T, Blumberg RS, et al
    Crohn's disease: NOD2, autophagy and ER stress converge.
    Gut. 2011;60:1580-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
18. TRAVIS SP , Schnell D, Krzeski P, Abreu MT, et al
    Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. DANESE S , Malesci A, Vetrano S
    Colitis-associated cancer: the dark side of inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
20. ROGLER G , Bernstein CN, Sood A, Goh KL, et al
    Role of biological therapy for inflammatory bowel disease in developing countries.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. BRAKENHOFF LK , van der Heijde DM, Hommes DW
    IBD and arthropathies: a practical approach to its diagnosis and management.
    Gut. 2011;60:1426-35.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. REHMAN A , Sina C, Gavrilova O, Hasler R, et al
    Nod2 is essential for temporal development of intestinal microbial communities.
    Gut. 2011;60:1354-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. USTUNDAG Y , Tezel A
    Dilate or wait for effective anti-inflammatory treatment for stenotic lesions associated with active inflammatory signs in Crohn's disease.
    Gut. 2011;60:1439.
    PubMed     Text format     Related articles   
    
    
    
    September 2011
24. SATSANGI J , Kennedy NA, Henderson P, Wilson DC, et al
    Exploring the hidden heritability of inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
25. BOUGUEN G , Peyrin-Biroulet L
    Surgery for adult Crohn's disease: what is the actual risk?
    Gut. 2011;60:1178-81.
    PubMed     Text format     Related articles   
    
    
    
    
26. PLANTINGA TS , Crisan TO, Oosting M, van de Veerdonk FL, et al
    Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2.
    Gut. 2011;60:1229-35.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
27. RAWSTHORNE P , Clara I, Graff LA, Bernstein KI, et al
    The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. HARITUNIANS T , Jones MR, McGovern DP, Shih DQ, et al
    Variants in ZNF365 isoform D are associated with Crohn's disease.
    Gut. 2011;60:1060-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
29. CULLEN G , Bader C, Korzenik JR, Sands BE, et al
    Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. TORRES J , Billioud V, Peyrin-Biroulet L, Colombel JF, et al
    Ulcerative colitis as a sole mucosal disease: another misunderstanding?
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
31. ROBLIN X , Neut C, Darfeuille-Michaud A, Colombel JF, et al
    Local appendiceal dysbiosis: the missing link between the appendix and ulcerative colitis?
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
32. RIDDLE MS , Porter CK
    Detection bias and the association between inflammatory bowel disease and Salmonella and Campylobacter infection.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
33. MARTEAU P
    Prebiotic carbohydrates: not sweet yet for Crohn's disease?
    Gut. 2011;60:882-3.
    PubMed     Text format     Related articles   
    
    
    
    
34. KAPPELMAN MD , Horvath-Puho E, Sandler RS, Rubin DT, et al
    Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study.
    Gut. 2011;60:937-43.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. BENJAMIN JL , Hedin CR, Koutsoumpas A, Ng SC, et al
    Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease.
    Gut. 2011;60:923-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. PEYRIN-BIROULET L , Oussalah A, Williet N, Pillot C, et al
    Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease.
    Gut. 2011;60:930-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
37. MARQUEZ L , Shen C, Cleynen I, De Hertogh G, et al
    Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. KIM SW , Kim ES, Moon CM, Park JJ, et al
    Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. PEYRIN-BIROULET L , Cieza A, Sandborn WJ, Coenen M, et al
    Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. ZUCCHELLI M , Camilleri M, Nixon Andreasson A, Bresso F, et al
    Association of TNFSF15 polymorphism with irritable bowel syndrome.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. PANES J , Benitez-Ribas D, Salas A
    Mesenchymal stem cell therapy of Crohn's disease: are the far-away hills getting closer?
    Gut. 2011;60:742-4.
    PubMed     Text format     Related articles   
    
    
    
    
42. CICCOCIOPPO R , Bernardo ME, Sgarella A, Maccario R, et al
    Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease.
    Gut. 2011;60:788-98.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. JANSE M , Weersma RK, Sudan DL, Festen EA, et al
    Association of Crohn's disease-associated NOD2 variants with intestinal failure requiring small bowel transplantation and clinical outcomes.
    Gut. 2011;60:877-8.
    PubMed     Text format     Related articles   
    
    
    
    May 2011
44. LIANG J , Zhang H, Wang D, Feng X, et al
    Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
45. BEN-HORIN S
    Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
46. VAN SCHAIK FD , van Oijen MG, Smeets HM, van der Heijden GJ, et al
    Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. RUST C , Brand S
    PSC: Protect and Serve with Colitis: does it help the liver to have severe ulcerative colitis?
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
48. MOWAT C , Cole A, Windsor A, Ahmad T, et al
    Guidelines for the management of inflammatory bowel disease in adults.
    Gut. 2011;60:571-607.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. REINISCH W , Stange EF
    Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease-the authors' response.
    Gut. 2011;60:739-40.
    PubMed     Text format     Related articles   
    
    
    
    
50. JOOSSENS M , Huys G, Cnockaert M, De Preter V, et al
    Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives.
    Gut. 2011;60:631-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
51. D'HAENS G , Ochsenkuhn T
    Current misunderstandings in the management of ulcerative colitis.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. LEIPER K , Martin K, Ellis A, Subramanian S, et al
    Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
53. LUTHER J , Owyang SY, Takeuchi T, Cole TS, et al
    Helicobacter pylori DNA decreases pro-inflammatory cytokine production by dendritic cells and attenuates dextran sodium sulphate-induced colitis.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. VELTKAMP C , Anstaett M, Wahl K, Moller S, et al
    Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNF{alpha} treatment.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. KUNISAKI KM
    Influenza vaccines in patients with IBD: ready for primetime?
    Gut. 2011;60:433-4.
    PubMed     Text format     Related articles   
    
    
    
    
56. WILDENBERG ME , van den Brink GR
    FXR activation inhibits inflammation and preserves the intestinal barrier in IBD.
    Gut. 2011;60:432-3.
    PubMed     Text format     Related articles   
    
    
    
    
57. AHMED T , Rieder F, Fiocchi C, Achkar JP, et al
    Pathogenesis of postoperative recurrence in Crohn's disease.
    Gut. 2011;60:553-62.
    PubMed     Text format     Related articles   
    
    
    
    March 2011
58. MARELLI L , Xirouchakis E, Kalambokis G, Cholongitas E, et al
    Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis?
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. VAN ASSCHE G
    Immunogenicity of anti-TNF antibodies. Has the veil been lifted?
    Gut. 2011;60:285-6.
    PubMed     Text format     Related articles   
    
    
    
    
60. WEISS G
    Iron in the inflammed gut: another pro-inflammatory hit?
    Gut. 2011;60:287-8.
    PubMed     Text format     Related articles   
    
    
    
    
61. WERNER T , Wagner SJ, Martinez I, Walter J, et al
    Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis.
    Gut. 2011;60:325-33.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
62. VERMEIRE S , Ghosh S, Panes J, Dahlerup JF, et al
    The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. ZIMMER KP , Heine M, Weissen-Plenz G, Scholand KA, et al
    TGF{alpha}-associated MUC2 and MUC3 expression of the gastric epithelium in Menetrier's disease during remission of ulcerative colitis.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
64. CAMILLERI M
    Managing symptoms of irritable bowel syndrome in patients with inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
65. SCHARL M , McCole DF, Weber A, Vavricka SR, et al
    Protein tyrosine phosphatase N2 regulates TNFalpha-induced signalling and cytokine secretion in human intestinal epithelial cells.
    Gut. 2011;60:189-97.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
66. KERR WG , Park MY, Maubert M, Engelman RW, et al
    SHIP deficiency causes Crohn's disease-like ileitis.
    Gut. 2011;60:177-88.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
67. RAHIER JF , Papay P, Salleron J, Sebastian S, et al
    H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. KASER A , Blumberg RS
    Lessons from type I interferons in ulcerative colitis.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
69. TRAVIS S
    Does it all ADA up? Adalimumab for ulcerative colitis.
    Gut. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
70. GADALETA RM , van Erpecum KJ, Oldenburg B, Willemsen EC, et al
    Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. DANESE S
    Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: 'brothers in arms'
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
72. REINISCH W , Sandborn WJ, Hommes DW, D'Haens G, et al
    Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.
    Gut. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. TRAVIS S , Satsangi J, Lemann M
    Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers.
    Gut. 2011;60:3-9.
    PubMed     Text format     Related articles   
    
    
    
    
74. HVIID A , Svanstrom H, Frisch M
    Antibiotic use and inflammatory bowel diseases in childhood.
    Gut. 2011;60:49-54.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
75. BEN-HORIN S , Yavzori M, Katz L, Kopylov U, et al
    The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful.
    Gut. 2011;60:41-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
76. JESS T , Simonsen J, Nielsen NM, Jorgensen KT, et al
    Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease.
    Gut. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. BAARS JE , Looman CW, Steyerberg EW, Kuipers EJ, et al
    Individualised surveillance strategies for colorectal cancer in inflammatory bowel disease.
    Gut. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
78. ELKJAER M , Shuhaibar M, Burisch J, Bailey Y, et al
    E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.
    Gut. 2010;59:1652-61.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
79. DUIJVESTEIN M , Vos AC, Roelofs H, Wildenberg ME, et al
    Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.
    Gut. 2010;59:1662-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
80. FORD AC
    Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease.
    Gut. 2010;59:1731-2.
    PubMed     Text format     Related articles   
    
    
    
    November 2010
81. COELHO J , Beaugerie L, Colombel JF, Hebuterne X, et al
    Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study.
    Gut. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. SANDBORN WJ , Colombel JF, Frankel M, Hommes D, et al
    Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis.
    Gut. 2010;59:1485-92.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
83. LEWIS JD
    Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease.
    Gut. 2010;59:1586-7.
    PubMed     Text format     Related articles   
    
    
    
    
84. MULLER S , Schaffer T, Flogerzi B, Seibold-Schmid B, et al
    Mannan-binding lectin deficiency results in unusual antibody production and excessive experimental colitis in response to mannose-expressing mild gut pathogens.
    Gut. 2010;59:1493-500.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
85. VAN ASSCHE G , Vermeire S, Rutgeerts P
    Management of acute severe ulcerative colitis.
    Gut. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
86. MOUSSATA D , Goetz M, Gloeckner A, Kerner M, et al
    Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo.
    Gut. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
87. MANNON PJ , Hornung RL, Yang Z, Yi C, et al
    Suppression of inflammation in ulcerative colitis by interferon-{beta}-1a is accompanied by inhibition of IL-13 production.
    Gut. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
88. RAMPTON DS
    The changing world of inflammatory bowel disease: impact of generation, gender and global trends.
    Gut. 2010;59:1446.
    PubMed     Text format     Related articles   
    
    
    
    
89. BEAUGERIE L , Gerbes AL
    Liver dysfunction in patients with IBD under immunosuppressive treatment: do we need to fear?
    Gut. 2010;59:1310-1.
    PubMed     Text format     Related articles   
    
    
    
    
90. ROBERTS CL , Keita AV, Duncan SH, O'Kennedy N, et al
    Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers.
    Gut. 2010;59:1331-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
91. ROLHION N , Barnich N, Bringer MA, Glasser AL, et al
    Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion.
    Gut. 2010;59:1355-62.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
92. FOELL D
    Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity.
    Gut. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
93. TURNER D , Leach ST, Mack D, Uusoue K, et al
    Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response.
    Gut. 2010;59:1207-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
94. BENDTZEN K , Steenholdt C, Ainsworth M, Thomsen OO, et al
    Comment on 'Predicting the response to infliximab from trough serum levels'.
    Gut. 2010;59:1298-9.
    PubMed     Text format     Related articles   
    
    
    
    
95. RAMADAS AV , Gunesh S, Thomas GA, Williams GT, et al
    Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates.
    Gut. 2010;59:1200-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
96. AL-SHAMMA S , Fox M, Campbell F, Collins P, et al
    Diarrhoea and weight loss in an immunosuppressed patient.
    Gut. 2010;59:1225.
    PubMed     Text format     Related articles   
    
    
    
    
97. BAUER C , Duewell P, Mayer C, Lehr HA, et al
    Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome.
    Gut. 2010;59:1192-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
98. MARKO B , Isabelle C, Tamara C, Gert VA, et al
    Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity.
    Gut. 2010.
    PubMed     Text format     Related articles   
    
    
    
    July 2010
99. PANES J , Ricart E, Rimola J
    New MRI modalities for assessment of inflammatory bowel disease.
    Gut. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
100. QASIM A , Ryan B, Breslin N, O'Morain C, et al
     Gastric retention and wireless capsule endoscopy in adults: a modified technique for direct duodenal deployment.
     Gut. 2010;59:1004-5.
     PubMed     Text format     Related articles   
     
     
     
     June 2010
101. SOKOL H , Seksik P, Carrat F, Nion-Larmurier I, et al
     Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
     Gut. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
102. LORAS C , Gisbert JP, Minguez M, Merino O, et al
     Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy.
     Gut. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
103. OUSSALAH A , Laurent V, Bruot O, Bressenot A, et al
     Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease.
     Gut. 2010.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
104. AKBAR A , Yiangou Y, Facer P, Brydon WG, et al
     Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain.
     Gut. 2010;59:767-74.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
105. DOTAN I , Rachmilewitz D, Schreiber S, Eliakim R, et al
     A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
     Gut. 2010;59:760-6.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
106. REINISCH W , Angelberger S, Petritsch W, Shonova O, et al
     Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
     Gut. 2010;59:752-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
107. SELMI C , Gershwin ME
     Autoantibodies in autoimmune liver disease: biomarkers versus epiphenomena.
     Gut. 2010;59:712-3.
     PubMed     Text format     Related articles   
     
     
     
     May 2010
108. IBEAKANMA C , Vanner S
     TNFalpha is a key mediator of the pronociceptive effects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons.
     Gut. 2010;59:612-21.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     
109. CAIRNS SR , Scholefield JH, Steele RJ, Dunlop MG, et al
     Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002).
     Gut. 2010;59:666-89.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     April 2010
110. MARTINEZ-AUGUSTIN O , Lopez-Posadas R, Gonzalez R, Ballester I, et al
     It may not be intestinal, but tissue non-specific alkaline phosphatase.
     Gut. 2010;59:560.
     PubMed     Text format     Related articles   
     
     
     
     
111. BARRETT KE
     Building better bugs to deliver biologics in intestinal inflammation.
     Gut. 2010;59:427-8.
     PubMed     Text format     Related articles   
     
     
     
     March 2010
112. TARGOWNIK LE
     Immortal time bias and infliximab-related mortality and malignancy incidence.
     Gut. 2010;59:416.
     PubMed     Text format     Related articles   
     
     
     
     
113. ZIMBWA T , Owen R, Thomas G, Hargest R, et al
     An unusual complication of colitis.
     Gut. 2010;59:364.
     PubMed     Text format     Related articles   
     
     
     
     
114. LAMB CA , Speight RA, Needham S, Graham JY, et al
     Management of Crohn's disease.
     Gut. 2010;59:340.
     PubMed     Text format     Related articles   
     
     
     
     
115. KOLTUN WA
     Long-term value of endoscopic dilatation for Crohn's strictures.
     Gut. 2010;59:288.
     PubMed     Text format     Related articles   
     
     
     
     
116. VAN ASSCHE G , Thienpont C, D'Hoore A, Vermeire S, et al
     Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy.
     Gut. 2010;59:320-4.
     PubMed     Text format     Related articles    Abstract available
     
     
     
     February 2010
117. ROGLER G
     The importance of gut microbiota in mediating the effect of NOD2 defects in inflammatory bowel disease.
     Gut. 2010;59:153-4.
     PubMed     Text format     Related articles   
     
     
     
     
118. COLLINS CB , McNamee EN, Wermers JD, Lebsack MD, et al
     Chemokine decoy receptor D6 in inflammatory bowel disease (IBD) and IBD-associated colon cancer.
     Gut. 2010;59:151-2.
     PubMed     Text format     Related articles   
     
     
     
     
119. PEYRIN-BIROULET L , Loftus EV Jr, Colombel JF, Sandborn WJ, et al
     Early Crohn disease: a proposed definition for use in disease-modification trials.
     Gut. 2010;59:141-7.
     PubMed     Text format     Related articles   
     
     
     
     
120. DANESE S , Gao B
     Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases.
     Gut. 2010;59:149-51.
     PubMed     Text format     Related articles   
     
     
     
     January 2010
121. RUTGEERTS P , Vermeire S, Van Assche G
     Predicting the response to infliximab from trough serum levels.
     Gut. 2010;59:7-8.
     PubMed     Text format     Related articles   
     
     
     
     October 2009
122. VETRANO S , Borroni EM, Sarukhan A, Savino B, et al
     The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6.
     Gut. 2009.
     PubMed     Text format     Related articles    Abstract available
     
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: